Navigation Links
PDL BioPharma to Announce Third Quarter 2013 Financial Results on November 6, 2013

INCLINE VILLAGE, Nev., Oct. 28, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its third quarter 2013 financial results for the period ended September 30, 2013, on Wednesday, November 6, 2013, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results.  A slide presentation relating to the call will be available via the webcast link on the PDL website.


Conference Call Details

To access the live conference call via phone, please dial (800) 668-4132 from the United States and Canada or (224) 357-2196 internationally. The conference ID is 93070209. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through November 12, 2013, and may be accessed by dialing (855) 859-2056 from the United States and Canada or (404) 537-3406 internationally. The replay passcode is 93070209.

To access the live and subsequently archived webcast of the conference call, go to the Company's website at and go to "Events & Presentations." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.

About PDL BioPharma

PDL BioPharma manages a portfolio of patents and royalty assets, consisting primarily of its Queen et al. antibody humanization patents and license agreements with various biotechnology and pharmaceutical companies. PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases for which it receives significant royalty revenue. PDL is currently focused on intellectual property asset management, investing in new income generating assets, and maximizing value for its shareholders.

The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL was founded in 1986 and is headquartered in Incline Village, Nevada.

In 2011, PDL initiated a strategy to bring in new income generating assets from the healthcare sector. To accomplish this goal, PDL seeks to provide non-dilutive growth capital and financing solutions to late stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions, and inventors. PDL successfully executed on this strategy by deploying over $125 million in 2012 and continues to pursue this strategic initiative. PDL is focused on the quality of the income generating assets and potential returns on investment. For more information, please visit

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

SOURCE PDL BioPharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Regeneron Named Top Employer in the Global Biopharmaceutical Industry for the Second Year in a Row
2. Bright Future Ahead for Biopharmaceutical Contract Manufacturing, Says Frost & Sullivan
3. Enteris BioPharma and Nordic BioSciences KeyBioScience Enter Strategic Licensing Agreement to Develop Metabolic Peptides Using Enteris Proprietary Oral Drug Delivery and Manufacturing Platform
4. CDISC and TransCelerate BioPharma Inc. Announce Landmark Asthma Data Standard Released for Public Review
5. Benu BioVentures to Finance Early Biopharmaceutical Clinical Development
6. Therapure Biopharma Inc. wins a 2013 CMO Leadership Award in All 5 Categories: Quality, Reliability, Innovation, Productivity and Regulatory
7. Recently Patented Technology Poised To Disrupt The Plasma Biopharmaceutical Market
8. Life Cycle Management of Biopharmaceuticals, New Life Science Webinar Hosted by Xtalks
9. KBI Biopharma Selects Freeslate’s Biologics Formulation System for Early and Late Stage Drug Development
10. 6th BSMA Annual Executive Summit to Address the Supply Chain Challenges and Solutions of Biopharma
11. Before the Bell Scans: Hologic Inc., St. Jude Medical Inc., ResMed Inc., and Navidea Biopharmaceuticals Inc.
Post Your Comments:
(Date:11/30/2015)... Nov. 30, 2015  AbbVie, is introducing Good ... on a daily routine for managing the life-long condition ... can affect the way the body absorbs it so ... a daily routine are important. The goal of the ... better manage their hypothyroidism by establishing a daily routine, ...
(Date:11/30/2015)... CA (PRWEB) , ... November ... ... Intelligence Company, today announced tighter software integration with MarkLogic, the Enterprise NoSQL ... organizations maximize information to drive change. , Smartlogic’s Content Intelligence capabilities provide ...
(Date:11/27/2015)... 27, 2015 /PRNewswire/--  Mallinckrodt plc (NYSE: MNK ... it has closed the sale of its global contrast ... NYSE Euronext) in a transaction valued at approximately $270 ... and a total of approximately 1,000 employees spread across ... St. Louis area. This entire workforce and ...
(Date:11/26/2015)... MUMBAI , November 26, 2015 ... --> Accutest Research ... accredited Contract Research Organization (CRO), has ... Chase Cancer Center - Temple Health ... ,     (Photo: ) ...
Breaking Biology Technology:
(Date:11/11/2015)... 11, 2015   MedNet Solutions , an innovative SaaS-based ... research, is pleased to announce that it will be a ... event, to be held November 17-19 in ... live demonstrations of iMedNet , MedNet,s easy-to-use, ... iMedNet has been able to deliver time and cost ...
(Date:11/9/2015)... , Nov. 09, 2015 ... the addition of the "Global Law ... their offering. --> ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) has ...
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
Breaking Biology News(10 mins):